

# SARS-CoV-2 viral load in the respiratory tract and in blood as factor associated to the clinical outcomes in adults with COVID-19 (COVID\_CV)

**First published:** 01/04/2020

**Last updated:** 06/04/2020

Study

Planned

## Administrative details

### EU PAS number

EUPAS34443

### Study ID

34579

### DARWIN EU® study

No

### Study countries

☐ Spain

### Study status

Planned

## Research institutions and networks

## Institutions

### Hospital Universitario Virgen del Rocío

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Networks

REIPI

## Contact details

### Study institution contact

Javier Sánchez Céspedes [jsanchez-ibis@us.es](mailto:jsanchez-ibis@us.es)

Study contact

[jsanchez-ibis@us.es](mailto:jsanchez-ibis@us.es)

### Primary lead investigator

Javier Sánchez Céspedes

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Planned: 06/04/2020

---

**Study start date**

Planned: 06/04/2020

---

**Date of final study report**

Planned: 06/04/2021

## Sources of funding

- Other

## More details on funding

REIPI, ISCIII

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

**Main study objective:**

To analyze the influence of the SARS-CoV-2 viral load in the lower respiratory tract (sputum, or invasive samples if clinically indicated), as well as in blood and feces (indicators of disseminated disease), as factors associated with the evolution of the disease, measured by the need for assisted ventilation and cure or death.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Medical condition to be studied**

Pneumonia

## Population studied

**Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)  
Adults (65 to < 75 years)  
Adults (75 to < 85 years)  
Adults (85 years and over)

---

### **Special population of interest**

Renal impaired  
Hepatic impaired  
Immunocompromised

---

### **Estimated number of subjects**

400

## **Study design details**

### **Outcomes**

Virologic variables will be included in an analysis together with demographics, co-morbidities, and the clinical and radiological characteristics of the pneumonia. Also, the sensitivity of the SARS-CoV-2 RT-PCR in nasopharyngeal swabs will be evaluated vs. sputum and viremia. Finally, the excretion and infectivity of the virus in feces will be determined after the patients are discharged, - Characterize viral load in: lower respiratory tract/blood/feces in COVID-19 pneumonia. - Analyze the association of viral load/presence of disseminated disease with the progression of pneumonia to respiratory failure and mortality. - Determine the diagnostic sensitivity of nasopharyngeal swabs vs. sputum and the excretion time in stool- Analyze the viability of the excreted virus in feces

---

## Data analysis plan

The inclusion of 400 patients diagnosed with COVID-19, their clinical evaluation and the virologic characterization of the infection in the proposed samples will provide us with information of key importance for the management of these patients. It will provide us with information on the optimal clinical sample to be used for greater sensitivity and specificity in the diagnosis of these patients. In addition, the evaluation of the viral load at each stage of the disease will allow us to stratify the cases based on their prognosis. The analysis of the excretion of the particles and their viability will be key when establishing adequate measures to minimize the transmission of the disease.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

[Other](#)

---

### Data sources (types), other

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

**CDM mapping**

No

Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

Data characterisation

**Data characterisation conducted**

No